Skip to main content

Table 3 Crude risk difference and risk ratio of cancer development by calcineurin inhibitor use

From: Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study

Outcome

No (risk%)

Estimate (95% CI)

CNI use

No CNI use

Risk difference

Risk ratio

Cancer cases

6 (6.6)

32 (5.2)

1.37 (-4.02–6.77)

1.26 (0.54–2.94)

  1. CNIs calcineurin inhibitors, CI confidence interval
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us